📚 Kiwoom Securities Industry Analysis: Strong Performance and Structural Expansion of the IB Segment - 2026.07.17

Hello, fans. This is Dotori, the Sector/Industry reporter for BultagiCom. Today, I want to examine the major trends related to Kiwoom Securities from an academic and systematic perspective. I will conduct this analysis by clarifying the causal relationships from the macroeconomic environment to micro-level corporate activities, so please follow along calmly.

📚 The Big Picture of the Industry and Structural Changes in the Securities Sector

According to systematic analysis, the securities industry is currently judged to have entered a cycle of overall strong performance. According to data from the financial investment industry, the combined net profit for the second quarter of this year for five major securities firms, including Kiwoom Securities, is estimated at approximately 3,208,700,000,000 KRW, a 9.7% increase compared to the previous quarter ^[1]. The background of this improved performance lies in the favorable winds of the global stock market. In fact, on July 15, the Korean stock market surged on the back of the strength of US tech stocks, and securities stocks also showed a simultaneous upward trend ^[2]. As a result, Kiwoom Securities' stock price rose 7.47% on that day to close at 331,000 KRW, drawing market attention ^[3]. For reference, the closing price as of July 17 was 322,000 KRW.

⚙️ Kiwoom Securities' Strategic Expansion and Value Chain Beneficiaries

Structurally, Kiwoom Securities is seeking expansion beyond simple brokerage into the IB segment and global markets. On the 15th, Kiwoom Securities successfully co-hosted the 'Hanmi × Kiwoom Bio Innovation Day' with Hanmi Pharmaceutical ^[4]. This event was designed to support IR pitching for 10 promising domestic bio-ventures and to provide a networking venue with investors such as venture capitalists ^[5]. Consequently, Kiwoom Securities clearly communicated its intention to strengthen investment banking (IB) activities in the bio sector to the market, emphasizing the importance of an open innovation strategy ^[6].

Interesting moves are also being observed from an overseas market perspective. Despite the Indonesian stock market suffering a slump, falling 30% since the beginning of the year, Kiwoom Securities' Indonesian subsidiary announced that it will adhere to its long-term growth strategy and focus on expansion ^[7].

Starting from the big picture of the industry, I will summarize the differential beneficiaries of the value chain in 1st, 2nd, and 3rd priority.

• 1st Priority: The brokerage business segment, which directly benefits from the increase in transaction volume due to global stock market tailwinds and recovery in investor sentiment.
• 2nd Priority: The investment banking (IB) segment, which secures new investment opportunities and deal sourcing networks by creating a collaboration ecosystem for bio-ventures.
• 3rd Priority: The Indonesian overseas subsidiary, which is preparing to expand local market share despite short-term difficulties.

🏭 Research Trends and Macroeconomic Outlook

The research capability, one of the inherent functions of a securities firm, is also being continuously demonstrated. According to an analysis by Ahn Ye-ha, a researcher at Kiwoom Securities, the US Federal Reserve is expected to proceed with additional interest rate hikes in October and continue the hiking trend until the first half of next year ^[8]. The market is closely watching this as the possibility remains open for interest rates to rise to 3.5% next year ^[8]. In terms of corporate analysis, the target price for Chong Kun Dang was lowered, citing the continued financial burden from investments in the bio-research complex and the resulting absence of short-term stock price momentum ^[9].

Therefore, Dotori believes that Kiwoom Securities' business diversification and research-based risk management strategies are effective from a mid-to-long-term perspective. I will return next time with more in-depth industry analysis.

📰 Reference News (9)

1

Securities Sector Q2

네이버뉴스 · 2026.07.16

📰 View original

3

[Up & Down] Securities Stocks Rise 6%, Samsung Securities ↑ · Shinyoung Securities ↓

네이버뉴스 · 2026.07.15

📰 View original

4

Hanmi Pharm-Kiwoom Securities, ‘Bio Innovation Day’ Successfully Held… Creating a Bio-Venture Collaboration Ecosystem - Law Issue

로이슈 · 2026.07.17

📰 View original

5

Hanmi Pharm-Kiwoom Securities ‘Bio Innovation Day’ Successfully Held

네이버뉴스 · 2026.07.17

📰 View original

6

Hanmi Pharm and Kiwoom Securities Connect Bio-Ventures and Investors at ‘Innovation Day’ - Money Today

머니투데이 · 2026.07.16

📰 View original

8

‘2.75%’ is the Expected Result… Market Focused on ‘When and How Much More Rates Will Rise’

네이버뉴스 · 2026.07.16

📰 View original

9

Kiwoom Securities "Lowering Chong Kun Dang Target Price, Financial Burden Continues Due to Bio-Research Complex Investment" - Business Post

비즈니스포스트 · 2026.07.16

📰 View original